ClinicalTrials.gg
CompletedNCT00648141Updated Apr 10, 2008

Safety and Efficacy of Celecoxib Versus Diclofenac in the Treatment of Ankylosing Spondylitis

A Phase 3 interventional study of Celecoxib and Celecoxib in Spondylitis, Ankylosing, sponsored by Pfizer. Completed at 47 sites in Germany. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2008-04-10.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
458
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Spondylitis, Ankylosing by Pfizer — 1 open to participants now, 1 under way, none of them phase 3. Spondylitis, Ankylosing · Pfizer.

Enrollment
2nd of 18
458 · median 129
Started
2003
the only one that year
Phase 3
7 of 34
none open now
Registered
14th of 34
by date

Among the 34 studies in Spondylitis, Ankylosing by Pfizer, this one is the 2nd largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2003, is one of 7 in phase 3, and was the 14th registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

1 of the 34 studies in Spondylitis, Ankylosing by Pfizer is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Spondylitis, Ankylosing by Pfizer, or all of them as a file.
02

Study summary

To compare the safety and efficacy of once-daily and twice-daily celecoxib versus diclofenac for the treatment of ankylosing spondylitis

03

Conditions studied

  • Spondylitis, Ankylosing
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ankylosing spondylitis defined according to modified New York criteria, and with axial involvement
  • Requiring daily treatment with nonsteroidal anti-inflammatory drugs during the previous 30 days

Exclusion criteria

Exclusion Criteria:

  • Patients with inflammatory enterophathy, and with extra-articular manifestations
  • Patients with known vertebral compression
  • Received 6 weeks prior to the baseline visit; patients on stable dose of prednisolone equivalents ≤ 10 mg/ day for at least 14 days before randomization were permitted
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
458 participants (actual)

Study arms

  • Experimental
    A

    Drug: Celecoxib

  • Experimental
    B

    Drug: Celecoxib

  • Active comparator
    C

    Drug: Diclofenac

Interventions

  • 200 mg oral capsule once daily for 12 weeks

  • 200 mg oral capsule twice daily for 12 weeks

  • 75 mg oral capsule twice daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Change from baseline in global pain intensity as assessed by visual analog scale (VAS)

    Time frame: Week 12

  2. Responder rates, defined as 50% improvement in VAS from baseline

    Time frame: Week 12

Secondary outcomes

  1. Patient's and physician's global assessment of disease activity

    Time frame: Weeks 1, 2, 6, and 12

  2. Spinal pain

    Time frame: Weeks 1, 2, 6, and 12

  3. Short Form-12

    Time frame: Weeks 1, 2, 6, and 12

  4. Adverse events

    Time frame: Week 12

  5. Physical evaluation

    Time frame: Week 12

  6. Laboratory tests

    Time frame: Week 12

  7. Nocturnal pain

    Time frame: Weeks 1, 2, 6, and 12

  8. Composite Bath Ankylosing Spondylitis Disease Activity Index

    Time frame: Weeks 1, 2, 6, and 12

  9. Bath Ankylosing Spondylitis Metrology Index

    Time frame: Weeks 1, 2, 6, and 12

  10. Change from baseline in C-reactive protein measurement

    Time frame: Week 12

  11. Responder rates, defined as 50% improvement in VAS from baseline

    Time frame: Weeks 1, 2, and 6

  12. Mobility parameters

    Time frame: Weeks 1, 2, 6, and 12

  13. Change from baseline in Assessments in Ankylosing Spondylitis 20 score

    Time frame: Weeks 1, 2, 6, and 12

  14. Change from baseline in global pain intensity

    Time frame: Weeks 1, 2, and 6

  15. Bath Ankylosing Spondylitis Functional Index

    Time frame: Weeks 1, 2, 6, and 12

07

Study locations

47 sites
  • Pfizer Investigational Site
    Aachen, 52064, Germany
  • Pfizer Investigational Site
    Bad Aibling, 83043, Germany
  • Pfizer Investigational Site
    Bad Iburg, 49186, Germany
  • Pfizer Investigational Site
    Bad Muender, 31848, Germany
  • Pfizer Investigational Site
    Berlin, 10559, Germany
  • Pfizer Investigational Site
    Berlin, 10777, Germany
  • Pfizer Investigational Site
    Berlin, 12200, Germany
  • Pfizer Investigational Site
    Berlin, 12247, Germany
  • Pfizer Investigational Site
    Berlin, 13125, Germany
  • Pfizer Investigational Site
    Berlin, 14059, Germany
  • Pfizer Investigational Site
    Berlin, D-10098, Germany
  • Pfizer Investigational Site
    Bonn, 53179, Germany
  • Pfizer Investigational Site
    Celle / OT Klein Hehlen, 29223, Germany
  • Pfizer Investigational Site
    Chemnitz, 09130, Germany
  • Pfizer Investigational Site
    Darmstadt, 64295, Germany
  • Pfizer Investigational Site
    Dresden, Germany
  • Pfizer Investigational Site
    Duesseldorf, 40211, Germany
  • Pfizer Investigational Site
    Elmshorn, 25335, Germany
  • Pfizer Investigational Site
    Erlangen, 91056, Germany
  • Pfizer Investigational Site
    Halle, 06128, Germany
  • Pfizer Investigational Site
    Hannover, 30161, Germany
  • Pfizer Investigational Site
    Heidelberg, 69120, Germany
  • Pfizer Investigational Site
    Hildesheim, 31134, Germany
  • Pfizer Investigational Site
    Hofheim, 65719, Germany
  • Pfizer Investigational Site
    Hoyerswerda, 02977, Germany
  • Pfizer Investigational Site
    Koeln, 51107, Germany
  • Pfizer Investigational Site
    Leipzig, 04107, Germany
  • Pfizer Investigational Site
    Leverkusen, 51373, Germany
  • Pfizer Investigational Site
    Magdeburg, 39104, Germany
  • Pfizer Investigational Site
    Mannheim, 68165, Germany
  • Pfizer Investigational Site
    Muenchen, 80336, Germany
  • Pfizer Investigational Site
    Neubrandenburg, 17033, Germany
  • Pfizer Investigational Site
    Oldenburg, 26121, Germany
  • Pfizer Investigational Site
    Osnabrueck, 49074, Germany
  • Pfizer Investigational Site
    Pirna, 01796, Germany
  • Pfizer Investigational Site
    Ratingen, D40882, Germany
  • Pfizer Investigational Site
    Regensburg, Germany
  • Pfizer Investigational Site
    Remscheid, 42897, Germany
  • Pfizer Investigational Site
    Rheine, 48431, Germany
  • Pfizer Investigational Site
    Rostock, 18059, Germany
  • Pfizer Investigational Site
    Saarbruecken, 66111, Germany
  • Pfizer Investigational Site
    Seesen, 38723, Germany
  • Pfizer Investigational Site
    Surwold, 26903, Germany
  • Pfizer Investigational Site
    Tuebingen, 72076, Germany
  • Pfizer Investigational Site
    Villingen-Schwenningen, 78054, Germany
  • Pfizer Investigational Site
    Weener, 26826, Germany
  • Pfizer Investigational Site
    Winsen/Luhe, 21423, Germany
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2003 and a completion of Jan 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2008
First posted
Apr 1, 2008
Start
Jan 2003
CompletionActual
Jan 2005
Last update
Apr 10, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00648141
Lead sponsor
Pfizer
First posted
Apr 1, 2008
Start date
Jan 2003
Completion
Jan 2005
Last update
Apr 10, 2008

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion